Godavari Drugs Intrinsic Value
Godavari Drugs (GODAVARI) median intrinsic value is ₹107.50 from 9 valuation models (range ₹38–₹248), vs current price ₹125.05 — -14.0% downside (Trading Above Median Value), margin of safety -16.3%. For current market price and key ratios, visit GODAVARI stock price BSE.
GODAVARI Valuation Methods Summary — DCF, Graham Number & P/E
Godavari Drugs intrinsic value across 9 models vs current price ₹125.05 — upside/downside and value range per method. Also explore Godavari Drugs share price performance to track price trends across different timeframes.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹107.80 | ₹86.24 - ₹129.36 | -13.8% | EPS: ₹4.90, Sector P/E: 22x |
| Book Value Method | asset | ₹107.50 | ₹96.75 - ₹118.25 | -14.0% | Book Value/Share: ₹53.75, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹247.50 | ₹222.75 - ₹272.25 | +97.9% | Revenue/Share: ₹123.75, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹150.00 | ₹135.00 - ₹165.00 | +20.0% | EBITDA: ₹12.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹186.77 | ₹149.42 - ₹224.12 | +49.4% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹37.52 | ₹33.77 - ₹41.27 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹69.29 | ₹62.36 - ₹76.22 | -44.6% | Revenue Growth: -11.4%, Adj P/E: 14.1x |
| ROE Based Valuation | profitability | ₹62.52 | ₹56.27 - ₹68.77 | -50.0% | ROE: 9.3%, P/E Multiple: 10x |
| Graham Defensive Method | conservative | ₹76.98 | ₹69.28 - ₹84.68 | -38.4% | EPS: ₹4.90, BVPS: ₹53.75 |
GODAVARI Intrinsic Value vs Market Price — All Valuation Models
Godavari Drugs fair value range ₹38–₹248 vs current market price ₹125.05 across 9 valuation models. Browse Godavari Drugs annual reports for revenue, profit, balance sheet and cash flow data.
GODAVARI Intrinsic Value Analysis — Undervalued or Overvalued?
Godavari Drugs median intrinsic value ₹107.50, current price ₹125.05 — Trading Above Median Value by 14.0%, margin of safety -16.3%.
What is the intrinsic value of GODAVARI?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Godavari Drugs (GODAVARI) is ₹107.50 (median value). With the current market price of ₹125.05, this represents a -14.0% variance from our estimated fair value.
The valuation range spans from ₹37.52 to ₹247.50, indicating ₹37.52 - ₹247.50.
Is GODAVARI undervalued or overvalued?
Based on our multi-method analysis, Godavari Drugs (GODAVARI) appears to be trading above median value by approximately 14.0%.
GODAVARI Financial Health — Key Ratios vs Industry Benchmarks
Godavari Drugs financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 2.93 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 9.3% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 11.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.69x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
GODAVARI Cash Flow Quality — Operating & Free Cash Flow
Godavari Drugs operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹11 Cr | ₹1 Cr | Positive Free Cash Flow | 7/10 |
| March 2024 | ₹18 Cr | ₹12 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹13 Cr | ₹9 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹11 Cr | ₹9 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹1 Cr | ₹1 Cr | Positive Free Cash Flow | 7/10 |